Alcon + Aerie, Novartis + Sandoz, Labcorp + RWJBH

Ophthalmology acquisitions, following the pharma trends, and a move in healthcare that is not technology related. 

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Alcon + Aerie
Novartis + Sandoz
Labcorp + RWJBH

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Bluebird, Endo & Pharmacies, Genentech + Jemincare, Merck + Orna

Gene therapy approval, opioid costs continue, a $650M deal, and a $3.5B RNA partnership.

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Bluebird
Endo & Pharmacies
Genentech + Jemincare
Merck + Orna

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Pfizer, Cerevel, Abbott, AstaZeneca + Daiichi Sankyo

Spending that COVID money, brain money, Irish money, and another oncology approval. 

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Pfizer
Cerevel
Abbott
AstaZeneca + Daiichi Sankyo

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Zymergen + Ginkgo, Cassava, Teva

This week, we take a break from stories of raising capital, mergers, and FDA approvals to look at the dark side of our industry. What happens when companies fail, people lie, and good drugs make bad lives?
 
Find out more at
https://LifeScienceTodayPodcast.com

Story References
Zymergen + Ginkgo
Cassava
Teva

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

ZyVersa, Incyte, Revolution, Frontera, CAMP4, ForSight, Auron

There’s a SPAC, expanded FDA approval, more of the common, and two Bs, two As

Find out more at
https://LifeScienceTodayPodcast.com

Story References
ZyVersa
Incyte
Revolution
Frontera
CAMP4
ForSight
Auron

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry. 

Vertex + ViaCyte, Theravance, Merck + Orion, Pliant, Qiming

Cell therapy acquisition, royalties sold, biobucks-like deal, successful raise, and Chinese Venture Capital

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Vertex + ViaCyte
Theravance Biopharma
Merck + Orion
Pliant Therapeutics
Qiming

About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.